###### Strengths and limitations of this study

-   This is the largest multicentre prospective study of fever of unknown origin (FUO) in Japanese hospitals.

-   The locations of the hospitals involved are geographically dispersed across the country, covering the eastern and western regions of Japan, representing the largest FUO data in Japan.

-   Key diagnostic features and the causes of FUO were analysed with respect to patients' medical histories, physical examination findings, standard blood tests and imaging examinations.

-   Despite this being the largest data sample collected from Japanese hospitals, the sample size is still small; caution should be taken when generalising the results.

Introduction {#s1}
============

Fever of unknown origin (FUO) has many possible causes which can vary depending on region and time period.[@R1] FUO was first described in the medical literature in 1930[@R4] and defined in 1961.[@R5] Since then, a significantly changing spectrum of diseases causing FUO has been reported.[@R6] The causes of FUO have now been classified as infections, non-infectious inflammatory diseases (NIID), malignancies, other conditions and unknown.[@R1] The proportion of different causative diseases of FUO has changed over time,[@R13] with fewer cases of FUO caused by infections and neoplasms over the past 40--50 years.[@R14] NIID is now the most common cause of FUO in adults,[@R1] while infectious diseases are most common in children.[@R16] In recent studies from Europe and the USA, the percentage of patients with unknown FUO varied from 7% to 53%.[@R9] Geographic factors may partly contribute to the proportion of FUO cases attributable to different causes.

Recent advances in immunohistopathology and modern imaging make the diagnosis of FUO easier, but definitive diagnosis is often difficult and cannot be achieved in up to 50% of cases.[@R2] Most previous studies of FUO have focused on its aetiology and prevalence,[@R3] outcomes or the diagnostic value of such tools as inflammatory markers[@R19] or positron emission tomography (PET).[@R21] However, limited studies have assessed the clinical utility of standard inflammatory markers, even though their use is now widespread.[@R1] The final diagnosis of FUO varies with age;[@R18] the most difficult to diagnose cases of FUO have no signs, with the causes remaining unknown.[@R2] Thus, FUO requires a specific diagnostic approach.

The medical evaluation of elderly patients requires a different perspective from that needed for younger patients.[@R18] Japan has a high proportion of elderly citizens. People aged 65 and older now constitute fully a quarter of the total population.[@R27] Recently, the first nationwide multicentre retrospective study of FUO in Japan was conducted, reporting the related diagnostic workup and identified diseases to consider when evaluating FUO.[@R1] However, the aetiology of FUO, its subjective symptoms and the usefulness of diagnostic tools and techniques in diagnosing FUO in the elderly had not been investigated in detail. The purpose of the multicentre prospective study is thus to update the current understanding of FUO with the addition of more patients in geographically dispersed Japanese hospitals. We aimed to identify the key symptoms and signs, diagnostic features and causes of FUO with respect to patient medical history, physical examination findings, standard blood tests and imaging examinations.

Patients and methods {#s2}
====================

Patients {#s2-1}
--------

This prospective study assessed patients aged ≥20 years with classic FUO from 16 hospitals (encompassing the eastern and western regions of Japan) affiliated with the Japanese Society of Hospital General Medicine, between January 2016 and December 2017. Classic FUO was diagnosed based on the definition used in Naito *et al*[@R1] in patients meeting all of the following criteria: (1) fever≥38.0°C at least twice within a 3-week period; (2) unknown aetiology of fever after three outpatient visits or 3 days of hospitalisation and (3) no diagnosis of immunodeficiency or confirmed HIV infection prior to fever onset.

The following data from patients were collected during a 6-month follow-up period and recorded on standardised case report forms: patient characteristics (sex, age, comorbidities, medical history and symptoms); physical examination; blood tests (blood count, general biochemical tests, inflammatory markers: erythrocyte sedimentation rate (ESR), C reactive protein (CRP) level, procalcitonin level); results of blood culture if performed; results of imaging studies and endoscopy if performed; results of cytology, histology and genetic testing or autopsy findings if performed and final diagnosis, day of diagnosis and follow-up diagnosis outcome. In addition to analysing the frequency of different causative diseases and outcomes of FUO cases, we evaluated the association between the presence or absence of examination for diagnostic evaluation, the number of days to diagnosis and the clinical follow-up results of inflammatory markers and other imaging tests.

Final diagnoses of the cause of FUO were classified into: infections, NIID, malignancies, other conditions and unknown. Unknown was defined as having no definitive diagnosis after 6 months of clinical investigation.

Statistical analysis {#s2-2}
--------------------

The authors developed cross-tables to present the number of patients and the percentage of those with a final diagnosis of FUO according to symptoms, diagnostic evaluation and time intervals. We performed χ² test to compare the differences between different classes of final diagnosis and all listed factors. We constructed logistic regression models to examine the likelihood of an unknown final diagnosis. All statistic assessments were two-sided and evaluated at the 0.05 level of significance. Statistical analyses were performed using IBM SPSS Statistics for Windows, V.22.0 (IBM, Armonk, New York, USA).

Patient and public involvement statement {#s2-3}
----------------------------------------

No patients or public were involved in the design and conduct of this study. Outcome measures were not affected by patient's experience or preferences.

Results {#s3}
=======

Patient characteristics {#s3-1}
-----------------------

A total of 141 patients who met the criteria of FUO were prospectively recruited from 16 hospitals, including 78 females (55.3%) and 63 males (44.7%), with a median age of 62 years (range: 22--94 years; IQR: 42--74 years). The largest age group was those 65--79 years (n=47). Infections (n=24; 17.0%) and NIID (n=48; 34.0%) constituted the most common known causes of fever in our patient population ([figure 1A](#F1){ref-type="fig"}). Infectious diseases included viral infection (n=5), infective endocarditis (n=4) and tuberculosis (n=2). The most common NIID were adult-onset Still disease (AOSD) (n=7), polymyalgia rheumatica (PMR) (n=6), antineutrophil cytoplasmic antibody-associated vasculitis (n=6) and rheumatoid arthritis (n=4). Twenty-two patients (15.6%) were diagnosed with malignant neoplasm, of whom 11 had malignant lymphoma. Seventeen patients (12.1%) were diagnosed with other causes, such as histiocytic necrotising lymphadenitis (n=3) and subacute thyroiditis (n=2). The cause in 21.3% (n=30) of cases remained unknown ([table 1](#T1){ref-type="table"}). Of all patients with FUO, more than 50% of those with infections, malignancy, NIID and other causes required \<100 days from the time of fever onset to the final diagnosis. NIID required the shortest time to be diagnosed (median 70.0 days, IQR: 54.5--107.5 days) ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).
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![Final diagnosis of FUO. The distribution of final diagnosis of FUO by causative disease (A), sex (B) and age group (\<65 years or older) (C). FUO, fever of unknown origin; NIID, non-infectious inflammatory disease.](bmjopen-2019-032059f01){#F1}

###### 

Description of final diagnosis of fever of unknown origin

  Final diagnosis                          N (%)
  ---------------------------------------- ------------
  Infectious disease                       24 (17.0%)
   Viral infection                         5
   Infective endocarditis                  4
   Tuberculosis                            2
  Malignancy                               22 (15.6%)
   Malignant lymphoma                      11
  Non-infectious inflammatory disease      48 (34.0%)
   Adult-onset Still disease               7
   Polymyalgia rheumatica                  6
   ANCA-associated vasculitis              6
   Rheumatoid arthritis                    4
  Others                                   17 (12.1%)
   Histiocytic necrotising lymphadenitis   3
   Subacute thyroiditis                    2
  Unknown                                  30 (21.3%)

ANCA, anti-neutrophil cytoplasmic antibody.

[Figure 1B,C](#F1){ref-type="fig"} show the distribution of the final diagnosis of FUO by sex and age. The final diagnosis of FUO had no significant correlation with sex ([figure 1B](#F1){ref-type="fig"}; χ^2^=1.0, df=4, p=0.916) but there was a significant correlation with age ([figure 1C](#F1){ref-type="fig"}; χ^2^=9.7, df=4, p=0.046). NIIDs constituted the major cause among patients aged ≥65 years (43.1%) and those \<65 years (26.3%). A lower percentage of patients aged ≥65 years (4.6%) were diagnosed with other causative diseases compared with those aged \<65 years (18.4%).

Symptoms and signs {#s3-2}
------------------

The comorbidities and symptoms in patients with FUO by final diagnosis are presented in [table 2](#T2){ref-type="table"}. Comorbidities included chronic conditions such as hypertension, diabetes and dyslipidaemia. A much higher percentage of patients with comorbidities were diagnosed with malignant neoplasm than those without (19.3% vs 9.6%). The major cause of FUO in patients without comorbidities was NIID (40.4%). Higher percentages of patients with respiratory (33.3%) and gastrointestinal (23.8%) symptoms were diagnosed with infectious diseases. Furthermore, the cause of FUO was NIID in most patients with symptoms of arthralgia (61.4%) or muscle pain (63.2%).

###### 

Characteristics of patients with fever of unknown origin by types of final diagnosis

  Variables\*                        Final diagnosis                                                       
  ---------------------------- ----- ----------------- ------------ ------------ ------------ ------------ ------------
  Comorbidity                  Yes   88                16 (18.2%)   17 (19.3%)   26 (29.5%)   10 (11.4%)   19 (21.6%)
  No                           52    8 (15.4%)         5 (9.6%)     21 (40.4%)   7 (13.5%)    11 (21.2%)   
  Subjective symptoms                                                                                      
   Headache                    Yes   23                3 (13.0%)    1 (4.3%)     9 (39.1%)    4 (17.4%)    6 (26.1%)
  No                           116   20 (17.2%)        21 (18.1%)   39 (33.6%)   12 (10.3%)   24 (20.7%)   
   Chest pain                  Yes   3                 1 (33.3%)    0 (0%)       1 (33.3%)    0 (0%)       1 (33.3%)
  No                           136   22 (16.2%)        22 (16.2%)   46 (33.8%)   17 (12.5%)   29 (21.3%)   
   Respiratory symptoms        Yes   24                8 (33.3%)    5 (20.8%)    2 (8.3%)     4 (16.7%)    5 (20.7%)
  No                           116   16 (13.8%)        17 (14.7%)   46 (39.7%)   13 (11.2%)   24 (21.6%)   
   Gastrointestinal symptoms   Yes   21                5 (23.8%)    4 (19.0%)    3 (14.3%)    2 (9.5%)     7 (33.3%)
  No                           119   19 (16.0%)        18 (15.1%)   44 (37.0%)   15 (12.6%)   23 (19.3%)   
   Stomach ache                Yes   14                2 (14.3%)    3 (21.4%)    5 (35.7%)    2 (14.3%)    2 (14.3%)
  No                           125   21 (16.8%)        19 (15.2%)   42 (33.6%)   15 (12.0%)   28 (22.4%)   
   Arthralgia                  Yes   44                5 (11.4%)    2 (4.5%)     27 (61.4%)   4 (9.2%)     6 (13.6%)
  No                           95    18 (18.9%)        20 (21.1%)   21 (22.1%)   12 (12.6%)   24 (25.3%)   
   Muscle pain                 Yes   19                2 (10.5%)    0 (0%)       12 (63.2%)   1 (5.3%)     4 (21.1%)
  No                           119   21 (17.6%)        21 (17.6%)   36 (30.3%)   15 (12.6%)   26 (21.8%)   
   Lymph node enlargement      Yes   15                2 (13.3%)    3 (20.0%)    3 (20.0%)    5 (33.3%)    2 (13.3%)
  No                           125   21 (16.8%)        19 (15.2%)   45 (36.0%)   12 (9.6%)    28 (22.4%)   
   Rash                        Yes   32                2 (6.3%)     6 (18.8%)    13 (40.6%)   5 (15.6%)    6 (18.8%)
  No                           109   22 (20.2%)        16 (14.7%)   35 (32.1%)   12 (11.0%)   24 (22.0%)   
   Diagnostic evaluation                                                                                   
   WBC‡                        Yes   141               24 (17.0%)   22 (15.6%)   48 (34.0%)   17 (12.1%)   30 (21.3%)
   CRP‡                        Yes   141               24 (15.6%)   22 (15.6%)   48 (34.0%)   17 (12.1%)   30 (21.3%)
   ESR                         Yes   115               14 (12.2%)   20 (17.4%)   40 (34.8%)   12 (10.4%)   29 (25.2%)
  No                           26    10 (38.5%)        2 (7.7%)     8 (30.8%)    5 (19.2%)    1 (3.8%)     
   Procalcitonin               Yes   54                8 (14.8%)    7 (13.0%)    20 (37.0%)   6 (11.1%)    13 (24.1%)
  No                           87    16 (18.4%)        15 (17.2%)   28 (32.2%)   11 (12.6%)   17 (19.5%)   
   Blood culture               Yes   125               23 (18.4%)   18 (14.4%)   42 (33.6%)   13 (10.4%)   29 (23.2%)
  No                           16    1 (6.3%)          4 (25.0%)    6 (37.5%)    4 (25.0%)    1 (6.3%)     
   Autopsy                     Yes   6                 1 (16.7%)    1 (16.7%)    2 (33.3%)    0 (0%)       2 (33.3%)
  No                           133   22 (16.5%)        20 (15.0%)   46 (34.6%)   17 (12.8%)   28 (21.1%)   
   PET                         Yes   44                4 (9.1%)     10 (22.7%)   16 (36.4%)   3 (6.8%)     11 (25.0%)
  No                           97    20 (20.6%)        12 (12.4%)   32 (33.0%)   14 (14.4%)   19 (19.6%)   
   Ga scintigraphy             Yes   40                2 (5.0%)     8 (20.0%)    16 (40.0%)   3 (7.5%)     11 (27.5%)
  No                           101   22 (21.8%)        14 (13.9%)   32 (31.7%)   14 (13.9%)   19 (18.8%)   

\*Missing data would not be reported.

†Percentage was calculated as number of patients who performed examination divided by total patients for each condition.

‡WBC and CRP were performed on all patients.

CRP, C reactive protein; ESR, erythrocyte sedimentation rate; Ga, gallium; NIID, non-infectious inflammatory disease; PET, positron emission tomography; WBC, white blood cells count.

Biochemical and imaging results {#s3-3}
-------------------------------

White blood cells (WBC) and CRP were examined in all patients, while 81.6% of patients were tested for ESR and 88.7% for blood culture ([online supplementary figure S1](#SP1){ref-type="supplementary-material"}). Only 38.3% of patients had procalcitonin tests. One in four or five patients underwent imaging scans (28.4% for gallium scintigraphy and 31.2% for PET). Autopsy was performed in only 4.3% of patients. Patients who underwent an ESR test had a greater likelihood of being diagnosed with a malignant neoplasm (17.4%) or unknown cause (25.2%) compared with those without an ESR test. Patients who had undergone an imaging examination had a relatively greater likelihood of being diagnosed with malignancy or NIID compared with those without imaging examinations ([table 2](#T2){ref-type="table"}).

There was a significant association between the aetiology of FUO and the prognosis of patients ([figure 2](#F2){ref-type="fig"}; χ^2^=27.6, df=12, p=0.006). Most patients with FUO with different causative diseases generally were cured or experienced relief. However, patients with malignancy or unknown causes had higher mortality rates (22.7% and 12.9%, respectively) ([figure 2](#F2){ref-type="fig"}). Among all 141 patients, the cause of fever was not identified in 104 patients at 2 months ([figure 3](#F3){ref-type="fig"}). At the end of the follow-up period, the cause of FUO remained unknown in 30 patients and 11 patients were not cured or had no symptom relief. Four deaths occurred among these patients. Pathological autopsy was performed on a small proportion of those who died (n=3); two cases remained unknown after autopsy ([figure 3](#F3){ref-type="fig"}).

![The distribution of final diagnosis of FUO by prognostic outcomes. There was an association between type of causative disease and prognosis (χ^2^=27.6, df=12, p=0.006). FUO, fever of unknown origin; NIID, non-infectious inflammatory disease.](bmjopen-2019-032059f02){#F2}

![Time course and prognostic outcomes for patients with FUO. FUO, fever of unknown origin.](bmjopen-2019-032059f03){#F3}

Tests were performed for diagnostic evaluation and abnormal readings were defined as in Naito *et al*:[@R1] WBC: 4000--8000; CRP: 0.3; ESR \>100 mm/hour and procalcitonin ≥0.25 ng/mL. Most patients with unknown cause of FUO had abnormal WBC and CRP levels (WBC: 56.7%; CRP: 73.3%, respectively), while a smaller percentage of patients had abnormal ESR and procalcitonin levels (ESR: 24.1%; procalcitonin: 23.1%). [Table 3](#T3){ref-type="table"} shows the association of patient demographics, clinical characteristics and diagnostic examinations for patients with known and unknown causes of FUO. There was a significant association between having undergone ESR examination and unknown final diagnosis of FUO (OR=8.43, 95% CI 1.09 to 65.00, p=0.041). Furthermore, 80% (28 of 35) of patients with an abnormal ESR value had a final diagnosis. No other variables differed significantly between the groups with known and unknown cause of FUO (all p\>0.05) ([table 3](#T3){ref-type="table"}).

###### 

The association of patient demographics, clinical characteristics and diagnostic evaluation between patients with known and unknown causes of FUO

  Variables                                  Known cause\*   Unknown cause\*   OR (95% CI)            P value†
  ---------------------------- ------------- --------------- ----------------- ---------------------- ----------
  Age group                    ≥65 years     53 (81.5%)      12 (18.5%)        0.73 (0.32 to 1.66)    0.451
  \<65 years                   58 (76.3%)    18 (23.7%)      1.00                                     
  Sex                          Male          48 (76.2%)      15 (23.8%)        1.31 (0.59 to 2.95)    0.510
  Female                       63 (80.8%)    15 (19.2%)      1.00                                     
  Comorbidity                  Yes           69 (78.4%)      19 (21.6%)        1.03 (0.44 to 2.37)    0.951
  No                           41 (78.8%)    11 (21.2%)      1.00                                     
  Symptoms                                                                                             
   Headache                    Yes           17 (73.9%)      6 (26.1%)         1.35 (0.48 to 3.80)    0.566
  No                           92 (79.3%)    24 (20.7%)      1.00                                     
   Chest pain                  Yes           2 (66.7%)       1 (33.3%)         1.85 (0.16 to 20.07)   0.622
  No                           107 (78.7%)   29 (21.3%)      1.00                                     
   Respiratory symptoms        Yes           19 (79.2%)      5 (20.8%)         1.01 (0.34 to 2.98)    0.987
  No                           92 (79.3%)    24 (20.7%)      1.00                                     
   Gastrointestinal symptoms   Yes           14 (66.7%)      7 (33.3%)         2.09 (0.76 to 5.76)    0.155
  No                           96 (80.7%)    23 (19.3%)      1.00                                     
   Stomach ache                Yes           12 (85.7%)      2 (14.3%)         0.58 (0.12 to 2.73)    0.489
  No                           97 (77.6%)    28 (22.4%)      1.00                                     
   Arthralgia                  Yes           38 (86.4%)      6 (13.6%)         0.47 (0.18 to 1.24)    0.127
  No                           71 (74.7%)    24 (25.3%)      1.00                                     
   Muscle pain                 Yes           15 (78.9%)      4 (21.1%)         0.95 (0.29 to 3.12)    0.938
  No                           93 (78.2%)    26 (21.8%)      1.00                                     
   Lymph node enlargement      Yes           13 (86.7%)      2 (13.3%)         0.53 (0.11 to 2.50)    0.425
  No                           97 (77.6%)    28 (22.4%)      1.00                                     
   Rash                        Yes           26 (81.3%)      6 (18.8%)         0.82 (0.30 to 2.21)    0.692
  No                           85 (78.0%)    24 (22.0%)      1.00                                     
  Ancillary findings                                                                                   
   WBC                         Yes           111 (78.7%)     30 (21.3%)        NA                     NA
  No                           0 (0%)        0 (0%)                                                   
   CRP                         Yes           111 (78.7%)     30 (21.3%)        NA                     NA
  No                           0 (0%)        0 (0%)                                                   
   ESR                         Yes           86 (74.8%)      29 (25.2%)        8.43 (1.09 to 65.00)   0.041
  No                           25 (96.2%)    1 (3.8%)        1.00                                     
   Procalcitonin               Yes           41 (75.9%)      13 (24.1%)        1.31 (0.58 to 2.96)    0.523
  No                           70 (80.5%)    17 (19.5%)      1.00                                     
   Blood culture               Yes           96 (76.8%)      29 (23.2%)        4.53 (0.57 to 35.78)   0.152
  No                           15 (93.8%)    1 (6.3%)        1.00                                     
   Autopsy                     Yes           4 (66.7%)       2 (33.3%)         1.88 (0.33 to 10.77)   0.481
  No                           105 (78.9%)   28 (21.1%)      1.00                                     
   PET                         Yes           33 (75.0%)      11 (25.0%)        1.37 (0.59 to 3.19)    0.468
  No                           78 (80.4%)    19 (19.6%)      1.00                                     
   Ga scintigraphy             Yes           29 (72.5%)      11 (27.5%)        1.64 (0.70 to 3.85)    0.258
  No                           82 (81.2%)    19 (18.8%)      1.00                                     

Stomach ache is different from gastrointestinal symptoms, which include vomiting and diarrhoea.

\*Percentage was calculated as the number of patients who received an examination divided by the total patients for each condition.

†χ² tests were performed.

CRP, C reactive protein; ESR, erythrocyte sedimentation rate; Ga, gallium; PET, positron emission tomography; WBC, white blood cell count.

Discussion {#s4}
==========

This prospective multicentre study represents the largest report of FUO data in Japanese patients to date. Of these 141 patients with FUO recruited from 16 hospitals, the most frequent age group was 65--79 years old, with the most frequent cause being NIID. There was a significant correlation between the final diagnosis of FUO and the age of patients (≥65 and\<65 years), but not with sex. While most studies have identified NIID as the most common cause of FUO in Japan,[@R1] our 2013 study found similar rates of NIID as a cause of FUO in participants ≥65 and \<65 years.[@R3] The different selection strategies of the age groups and the ageing of the Japanese population may contribute to the differences in these findings between studies. In Japan, adults age ≥65 accounted for 26.7% of the 127.11 million population in 2016,[@R27] and will increase to 40% in 2050, according to a new analysis.[@R31] In this study, 46.1% of patients were ≥65 years, an increase since 2013 (42.1%).[@R3] Moreover, this trend should also be considered in Western countries, where ageing of the population is also expected.[@R31] A diagnosis of NIID, which occurs significantly more often in elderly patients,[@R1] consequently must be considered first for an FUO, particularly in patients ≥65 years. Of interest, AOSD was the most frequent NIID cause of FUO in this population. Several factors may explain this seemingly high proportion (5%). One possible justification could be that these patients may have AOSD susceptibility genes. Susceptibility of AOSD in the Japanese population depends on the genotype combinations of the HLD DRB1 and DQB1 alleles, and predisposing risk has been found associated with the haplotype DRB1\*15:01-DQB1\*06:02 in Japanese patients with AOSD.[@R32] However, genotyping results were not available for this study.

Difference in causative disease between populations could be influenced by factors such as geographic location, zoonotic characteristics and the economic and medical organisation of the local healthcare system. Infectious disease was the leading cause of FUO in South-East Europe, as reported by Baymakova *et al* in 2016.[@R33] Infection was the second most common causes of fever in our patient population. Our previous study in 2013 demonstrated that PMR and HIV should be considered as causes of FUO.[@R3] However, HIV was not found in this study, possibly due to the efficiency of HIV testing in Japan. The frequency of unknown cause in our study was comparable to that found previously in 2013.[@R3]

The availability of new diagnostic techniques, including CT, PET imaging, improved culture techniques and advanced serological assays, has changed both the spectrum of diseases causing FUO and the time to reveal the final diagnosis. In a previous study, the cause of FUO diagnosed after ≥100 days was malignancy.[@R3] In this study, more than 50% of patients with FUO with infections, malignancy, NIID and other causes had a final diagnosis within 100 days of fever onset. Similarly, in a series of patients with FUO studied in Europe and USA, 30%--50% were of unknown cause after a follow-up of ≥100 days.[@R6]

In the present study, we evaluated key symptoms and signs in patients with FUO to determine which were diagnostically useful. We found that comorbidities were the main symptoms and signs in FUO caused by malignant neoplasms. Patients with infectious diseases often had respiratory and gastrointestinal symptoms, while those with NIID often had arthralgia or muscle pain. Although the various symptoms/signs were not directly related to the final diagnosis of FUO,[@R14] their presence might help improve the differential diagnosis in patients with FUO.

A systemic review from 2003 reported that the prevalence of FUO was 1.5%--3% in all hospitalised patients, and mortality in these patients was 12%--35%.[@R35] We found that the aetiology of FUO was significantly associated with prognosis; patients with FUO diagnosed with malignancy or unknown causes had higher mortality rates. A Danish study also found that patients with FUO with malignancy had poor prognosis.[@R36] Little is known about the prognosis of patients with FUO of unknown cause. In our study, 4 of 30 (13.3%) patients with FUO of unknown cause died during within 6 months; the cause of FUO remained unknown after autopsy in two of these patients. In patients with FUO of unknown cause, Dutch studies showed mortality rates of 2.0%--4.0%[@R6] and other western-European studies reported mortality rates of 2.0%--19.0%.[@R7] The variances among studies may be due to differences in patient selection, study design or healthcare systems.

Since there is no standard diagnostic approach in FUO, classic test features are difficult to apply in FUO studies. Of all positive biochemical tests, only 1.7% contributed indirectly to diagnosis in a Turkey FUO study.[@R13] Despite advances in diagnostic tests and techniques, a significant proportion of all cases remains undiagnosed.[@R40] Our previous study found that 14.9% of patients with FUO had an ESR \>100 mm/hour, including 5 with FUO of unknown cause.[@R1] In the current study, 35 of 115 patients (30.4%) had an abnormal ESR test result; in these, the cause of FUO was identified in 80% of patients. In addition, there was a significant association between known cause and ancillary ESR test, but not with other variables such as procalcitonin or PET. Therefore, the current study demonstrated the usefulness of ESR in evaluating FUO. However, further investigation is required. We speculate that future FUO research may be leaving the twilight zone as diagnostic microcellular research technologies emerge from the laboratory to point-of-care rapid diagnostic kits. We await further advances in diagnostic artificial intelligence to expose FUO cause in more cases.[@R41]

The present study has the following limitations. First, despite this being the largest data sample ever collected from geographically dispersed Japanese hospitals, the sample size is still small; caution should be taken when generalising our results. Also, we did not establish uniformity of the diagnostic criterion used in this study, which may have resulted in overdiagnosis or underdiagnosis of specific disease categories. Uncertainty of diagnosis was not addressed. Finally, our follow-up database was not designed to include records of spontaneous fever remission.[@R43]

In conclusion, evaluating and determining the cause of a fever is complex. The availability of new diagnostic techniques (including CT and PET imaging), improved culture techniques and recent advances in serological assays have all changed both the spectrum of diseases causing FUO and the time needed to reach a final diagnosis. Our study identified age and ESR as potentially important factors useful in assisting clinicians navigate the paths to diagnosing FUO. These advances, together with future development of multimicrobial and cancer cell detection tools, may allow faster determination of the causes of FUO and further improve the prognosis of patients with FUO.
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